218 related articles for article (PubMed ID: 37726808)
1. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
[TBL] [Abstract][Full Text] [Related]
2. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
[TBL] [Abstract][Full Text] [Related]
3. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
[TBL] [Abstract][Full Text] [Related]
4. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
McDermott GC; DiIorio M; Kawano Y; Jeffway M; MacVicar M; Dahal K; Moon SJ; Seyok T; Coblyn J; Massarotti E; Weinblatt ME; Weisenfeld D; Liao KP
Semin Arthritis Rheum; 2024 Jun; 66():152421. PubMed ID: 38457949
[TBL] [Abstract][Full Text] [Related]
5. Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems.
Watanabe R; Okano T; Gon T; Yoshida N; Fukumoto K; Yamada S; Hashimoto M
Front Med (Lausanne); 2022; 9():1049875. PubMed ID: 36353219
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.
Roodenrijs NMT; Hamar A; Kedves M; Nagy G; van Laar JM; van der Heijde D; Welsing PMJ
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33419871
[TBL] [Abstract][Full Text] [Related]
7. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
8. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study.
Michitsuji T; Fukui S; Morimoto S; Endo Y; Nishino A; Nishihata S; Tsuji Y; Shimizu T; Umeda M; Sumiyoshi R; Koga T; Iwamoto N; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Ohtsubo H; Takaoka H; Hamada H; Tsuru T; Nawata M; Arinobu Y; Hidaka T; Tada Y; Kawakami A; Kawashiri SY
Scand J Rheumatol; 2024 Mar; 53(2):123-129. PubMed ID: 38085537
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis.
Yoshii I; Sawada N; Chijiwa T
Rheumatol Int; 2022 Nov; 42(11):1947-1954. PubMed ID: 35410410
[TBL] [Abstract][Full Text] [Related]
10. Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes.
David P; Di Matteo A; Hen O; Dass S; Marzo-Ortega H; Wakefield RJ; Bissell LA; Nam J; Mankia K; Emery P; Saleem B; McGonagle D
Arthritis Rheumatol; 2024 Apr; 76(4):510-521. PubMed ID: 38059326
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry.
Koh JH; Lee SK; Kim J; Kim HA; Shin K; Min JK
Clin Exp Rheumatol; 2021; 39(2):269-278. PubMed ID: 32324126
[TBL] [Abstract][Full Text] [Related]
12. 'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.
Tan Y; Buch MH
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896282
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.
Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ohmura K; Ito H; Matsuda S
Immunol Med; 2022 Mar; 45(1):35-44. PubMed ID: 34033729
[TBL] [Abstract][Full Text] [Related]
14. Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study.
Lee SK; Shin K; Jung JY; Suh CH; Kim JW; Kim HA
BioDrugs; 2023 Mar; 37(2):247-257. PubMed ID: 36757601
[TBL] [Abstract][Full Text] [Related]
15. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
[TBL] [Abstract][Full Text] [Related]
16. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study.
Giollo A; Zen M; Larosa M; Astorri D; Salvato M; Calligaro A; Botsios K; Bernardi C; Bianchi G; Doria A
Rheumatology (Oxford); 2023 Jun; 62(6):2083-2089. PubMed ID: 36190344
[TBL] [Abstract][Full Text] [Related]
17. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
18. Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry.
Ochi S; Mizoguchi F; Nakano K; Tanaka Y
Clin Exp Rheumatol; 2022 Jan; 40(1):86-96. PubMed ID: 33635223
[TBL] [Abstract][Full Text] [Related]
19. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.
Garcia-Salinas R; Sanchez-Prado E; Mareco J; Ronald P; Ruta S; Gomez R; Magri S
Rheumatol Int; 2023 Oct; 43(10):1821-1828. PubMed ID: 37269430
[TBL] [Abstract][Full Text] [Related]
20. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
